Novelty Nobility Expands Manufacturing Pact With AGC Biologics in Japan

Novelty Nobility is expanding a manufacturing agreement with AGC Biologics to advance a bispecific antibody drug candidate in Japan. The candidate will progress through process development and good manufacturing practice (GMP) manufacturing at AGC Biologics’ facility in Chiba, Japan. AGC Biologics defines itself as a global pharmaceutical CDMO. Meanwhile, Novelty Nobility, based in South Korea,…

Read More

CTO Presents 2026 Caribbean Sustainable Tourism Award Winners | News

The Caribbean Tourism Organization (CTO) has unveiled the winners of the 2026 Caribbean Sustainable Tourism Awards, spotlighting top-tier innovation in the region’s journey toward sustainable and regenerative tourism. Honorees from Belize, Guyana, Jamaica and Turks and Caicos Islands were recognized for their leadership in pioneering sustainable tourism practices that protect the Caribbean’s natural and cultural…

Read More

Antigua and Barbuda Gears Up for Caribbean Travel Marketplace | News

As the Caribbean prepares for a busy spring and summer tourism calendar, Colin James, Chief Executive Officer of the Antigua and Barbuda Tourism Authority, says the destination is in advanced stages of readiness to host and capitalize on back-to-back editions of the Caribbean Hotel and Tourism Association’s (CHTA) Caribbean Travel Marketplace, May 12-15, at the…

Read More

Chelsea suffer another head injury vs Nottingham Forest as bloodied Robert Sanchez forced off

Chelsea endured the worst possible bank holiday at Stamford Bridge with two serious head injuries taking place during their home game against Nottingham Forest 16:41, 04 May 2026Updated 17:10, 04 May 2026 Robert Sanchez suffered a head injury against Nottingham Forest(Image: Sky) Robert Sanchez was left bloodied after he became the second Chelsea player to…

Read More

UCB Agrees to Acquire Candid Therapeutics

UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). Under the terms of the agreement, UCB will pay $2 billion upfront payments and up to $200 million in potential future milestone…

Read More